eligibility_summary
Eligibility: recurrent/persistent endometrial carcinoma or carcinosarcoma, <=3 prior systemic lines (incl platinum and anti-PD-1/PD-L1), eligible for doxorubicin or paclitaxel, radiologically evaluable disease (RECIST v1.1), ECOG 0-1, adequate organ function. Exclude: leiomyosarcoma/stromal sarcoma, curative-intent candidates, platinum rechallenge, prior Trop-2 ADC, active second cancer, serious infection, active IBD/recent GI perforation, pregnancy/breastfeeding. Other criteria apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3, randomized, open-label trial in previously platinum- and anti–PD-1/PD-L1–treated endometrial cancer comparing sacituzumab govitecan-hziy (SG) vs physician’s choice (doxorubicin or paclitaxel). SG: antibody-drug conjugate targeting Trop-2, humanized anti–Trop-2 mAb linked to SN-38 (topoisomerase I inhibitor) to deliver cytotoxic payload to Trop-2–expressing tumor cells, causing DNA damage and bystander killing. Doxorubicin: anthracycline, DNA intercalation, topoisomerase II inhibition, ROS. Paclitaxel: taxane, microtubule stabilization, mitotic arrest. Targets/pathways: Trop-2+ epithelial tumor cells, topo I/II DNA replication/repair, microtubule/mitotic spindle.